(Q37638152)

21 August 2017

1 reference

title

Cardiovascular effects of relaxin: from basic science to clinical therapy (English)

1 reference

21 August 2017

1 reference

2

Ross A D Bathgate

1 reference

21 August 2017

Roger J Summers

5

0 references

Anthony M Dart

object named as

Anthony M Dart

series ordinal

4

0 references

author name string

Xiao-Jun Du

series ordinal

1

1 reference

PubMed ID

19935741

21 August 2017

Chrishan S Samuel

series ordinal

3

1 reference

PubMed ID

19935741

21 August 2017

language of work or name

English

0 references

publication date

24 November 2009

1 reference

Nature Reviews Cardiology

21 August 2017

1 reference

21 August 2017

7

1 reference

21 August 2017

1

1 reference

21 August 2017

48-58

1 reference

Relaxin's physiological roles and other diverse actions

21 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Purification and characterization of porcine relaxin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Structure of a genomic clone encoding biologically active human relaxin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

'Relaxin' the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin: a pleiotropic hormone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin: antifibrotic properties and effects in models of disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin increases secretion of matrix metalloproteinase-2 and matrix metalloproteinase-9 during uterine and cervical growth and remodeling in the pig

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin increases secretion of tissue inhibitor of matrix metalloproteinase-1 and -2 during uterine and cervical growth and remodeling in the pig

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Activation of orphan receptors by the hormone relaxin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

International Union of Pharmacology LVII: recommendations for the nomenclature of receptors for relaxin family peptides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

The insulin-like growth factor-II/mannose-6-phosphate receptor: structure, distribution and function in the central nervous system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Modulation of insulin action.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

New insights into the evolution of the relaxin-LGR signaling system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

The relaxin receptor-binding site geometry suggests a novel gripping mode of interaction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

The trap-like relaxin-binding site of the leucine-rich G-protein-coupled receptor 7

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Multiple binding sites revealed by interaction of relaxin family peptides with native and chimeric relaxin family peptide receptors 1 and 2 (LGR7 and LGR8).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

H3 relaxin is a specific ligand for LGR7 and activates the receptor by interacting with both the ectodomain and the exoloop 2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Characterization of novel splice variants of LGR7 and LGR8 reveals that receptor signaling is mediated by their unique low density lipoprotein class A modules

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Defining the LGR8 residues involved in binding insulin-like peptide 3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

The A-chain of human relaxin family peptides has distinct roles in the binding and activation of the different relaxin family peptide receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

The NMR solution structure of the relaxin (RXFP1) receptor lipoprotein receptor class A module and identification of key residues in the N-terminal region of the module that mediate receptor activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Phosphoinositide 3-kinase activity is required for biphasic stimulation of cyclic adenosine 3',5'-monophosphate by relaxin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin stimulates protein kinase C zeta translocation: requirement for cyclic adenosine 3',5'-monophosphate production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin family peptide receptor (RXFP1) coupling to G(alpha)i3 involves the C-terminal Arg752 and localization within membrane Raft Microdomains.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

RXFP1 couples to the Galpha-Gbetagamma-PI3K-PKCzeta pathway via the final 10 amino acids of the receptor C-terminal tail.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin peptides are new global players.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin activates the MAP kinase pathway in human endometrial stromal cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin antagonizes hypertrophy and apoptosis in neonatal rat cardiomyocytes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Demonstration of a relaxin receptor and relaxin-stimulated tyrosine phosphorylation in human lower uterine segment fibroblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Emerging role of relaxin in renal and cardiovascular function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Protective effects of relaxin in ischemia/reperfusion-induced intestinal injury due to splanchnic artery occlusion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Effect of relaxin on myocardial ischemia injury induced by isoproterenol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin as an additional protective substance in preserving and reperfusion solution for liver transplantation, shown in a model of isolated perfused rat liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin inhibits lipopolysaccharide‐induced adhesion of neutrophils to coronary endothelial cells by a nitric oxide‐mediated mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin up-regulates inducible nitric oxide synthase expression and nitric oxide generation in rat coronary endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin counteracts myocardial damage induced by ischemia-reperfusion in isolated guinea pig hearts: evidence for an involvement of nitric oxide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin-induced increased coronary flow through stimulation of nitric oxide production.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Protective effect of relaxin in cardiac anaphylaxis: involvement of the nitric oxide pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin-induced reduction of infarct size in male rats receiving MCAO is dependent on nitric oxide synthesis and not estrogenic mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Evidence against the hypothesis that endothelial endothelin B receptor expression is regulated by relaxin and pregnancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Identification of the pregnancy hormone relaxin as glucocorticoid receptor agonist.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

RXFP1-inactive relaxin activates human glucocorticoid receptor: further investigations into the relaxin-GR pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin-a pleiotropic hormone and its emerging role for experimental and clinical therapeutics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

The vascular actions of relaxin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin increases cardiac output and reduces systemic arterial load in hypertensive rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Recombinant human relaxin reduces hypoxic pulmonary hypertension in the rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Chronic decrease of blood pressure by rat relaxin in spontaneously hypertensive rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Mechanisms of renal vasodilation and hyperfiltration during pregnancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Renal function during normal pregnancy and preeclampsia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Effects of relaxin on systemic arterial hemodynamics and mechanical properties in conscious rats: sex dependency and dose response.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Paracrine effects of transplanted myoblasts and relaxin on post-infarction heart remodelling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Central hemodynamic effects of recombinant human relaxin in the isolated, perfused rat heart model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin stimulates atrial natriuretic peptide secretion in perfused rat heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Cardiac effects of relaxin in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin increases rat heart rate by a direct action on the cardiac atrium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Comparison of relaxin receptors in rat isolated atria and uterus by use of synthetic and native relaxin analogues.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Quantitative autoradiographic studies of relaxin binding in rat atria, uterus and cerebral cortex: characterization and effects of oestrogen treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Adenovirus-mediated delivery of relaxin reverses cardiac fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Functional and histopathological improvement of the post-infarcted rat heart upon myoblast cell grafting and relaxin therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: a gender-specific phenotype.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Reversal of cardiac fibrosis and related dysfunction by relaxin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

31 March 2020

Regenerating the heart

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Morphofunctional integration between skeletal myoblasts and adult cardiomyocytes in coculture is favored by direct cell-cell contacts and relaxin treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Skeletal myoblasts overexpressing relaxin improve differentiation and communication of primary murine cardiomyocyte cell cultures

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

The pregnancy hormone relaxin is a player in human heart failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Endogenous relaxin does not affect chronic pressure overload-induced cardiac hypertrophy and fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin is an independent risk factor predicting death in male patients with end-stage kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Is the pregnancy hormone relaxin an important player in human heart failure?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Circulating levels of relaxin and its relation to cardiovascular function in patients with hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

The relationship between hCG and relaxin secretion in normal pregnancies vs peri-implantation spontaneous abortions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

The disposition of a human relaxin (hRlx-2) in pregnant and nonpregnant rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin, a pleiotropic vasodilator for the treatment of heart failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Myofibroblasts induce ectopic activity in cardiac tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

In vitro decidualization of human endometrial stromal cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin activates multiple cAMP signaling pathway profiles in different target cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin potentiates the expression of inducible nitric oxide synthase by endothelial cells from human umbilical vein in in vitro culture.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin activates the L-arginine-nitric oxide pathway in vascular smooth muscle cells in culture.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin is essential for systemic vasodilation and increased global arterial compliance during early pregnancy in conscious rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Influence of recombinant human relaxin on renal hemodynamics in healthy volunteers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin family peptide receptors--former orphans reunite with their parent ligands to activate multiple signalling pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Time course and dose response of relaxin-mediated renal vasodilation, hyperfiltration, and changes in plasma osmolality in conscious rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Prolonged RXFP1 and RXFP2 signaling can be explained by poor internalization and a lack of beta-arrestin recruitment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Structural basis of allosteric ligand-receptor interactions in the insulin/relaxin peptide family: implications for other receptor tyrosine kinases and G-protein-coupled receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Dimerization and negative cooperativity in the relaxin family peptide receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Negative cooperativity in H2 relaxin binding to a dimeric relaxin family peptide receptor 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Relaxin binding in the rat heart atrium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Myocardial relaxin counteracts hypertrophy in hypertensive rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.198

Structural biology of insulin and IGF-1 receptors.

31 March 2020

1 reference

12 December 2020

Relaxin protects against myocardial injury caused by ischemia and reperfusion in rat heart

1 reference

12 December 2020

Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts

1 reference

12 December 2020

Relaxin family peptide receptors RXFP1 and RXFP2 modulate cAMP signaling by distinct mechanisms

1 reference

12 December 2020

Relaxin gene expression in human ovaries and the predicted structure of a human preprorelaxin by analysis of cDNA clones

1 reference

12 December 2020

Relaxin prevents the development of severe acute pancreatitis

1 reference

12 December 2020

Serum relaxin in systemic sclerosis.

1 reference

12 December 2020

10.1038/NRCARDIO.2009.198

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zmk2rwz335d67cbapgjqoqdvmu

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_zmk2rwz335d67cbapgjqoqdvmu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zmk2rwz335d67cbapgjqoqdvmu

30 July 2022

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/zmk2rwz335d67cbapgjqoqdvmu

30 July 2022